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Abstract
Introduction: BRAF (v raf murine sarcoma viral oncogene homologue B1) is a serine-threonine kinase involved in
the mitogen-activated protein kinase (MAPK) signalling pathway, known to be implicated in the production of pro-
inflammatory cytokines.
We have observed that sera from rheumatoid arthritis (RA) patients recognize the BRAF’s catalytic domain, which
encompasses amino acids 416 to 766. Here, we identify peptide targets of anti-BRAF autoantibodies and test
whether anti-BRAF autoantibodies may interfere with BRAF kinase activity.
Methods: Anti-BRAF autoantibodies were detected by ELISA (enzyme-linked immunosorbent assay) in the serum of
RA patients and controls, using 40 overlapping 20mer peptides encompassing the catalytic domain of BRAF as
immunosorbents. To test whether autoantibodies to BRAF influence BRAF kinase activity, we developed an in vitro
phosphorylation assay of MEK1 (mitogen extracellular regulated kinase), a major BRAF substrate. MEK1
phosphorylation by BRAF was tested in the presence of purified anti-BRAF autoantibodies from RA patients or
control antibody.
Results: We found that one BRAF peptide, P25 (656 to 675), is specifically recognized by autoantibodies from RA
patients. Of interest, anti-P25 autoantibodies are detected in 21% of anti-CCP (cyclic citrullinated peptides) negative
RA patients. Anti-BRAF autoantibodies activate the in vitro phosphorylation of MEK1 mediated by BRAF.
Conclusions: Anti-BRAF autoantibodies from RA patients preferentially recognize one BRAF peptide: P25.
Autoantibody responses to P25 are detected in 21% of anti-CCP negative RA patients. Most anti-BRAF
autoantibodies activate BRAF kinase activity.
Introduction
Rheumatoid arthritis (RA) is a chronic inflammatory
joint disease with a prevalence of 0.5% worldwide [1].
The mechanisms leading to RA are unknown. The sera
of RA patients contain many autoantibodies. The most
characteristic are directed at citrullinated proteins
(ACPA) [2]. ACPA recognize citrulline (a posttransla-
tionally modified form of arginin) containing epitopes
on various proteins, such as filaggrin, vimentin, and
fibrinogen [3-6]. ACPAs can be detected by commer-
cially available enzyme-linked immunoabsorbent assays
using synthetic cyclic citrullinated peptides (CCP). Anti-
CCP antibodies are detected in 60% of RA patients.
Non-citrullinated proteins can also be the target of
autoantibodies in RA [7,8].
By screening protein arrays, we found that BRAF
(v raf murine sarcoma viral oncogene homologue B1) is
a major non-itrullinated autoantigen recognized by 35%
of RA patients’ sera [8]. BRAF encodes a 766 amino
acid serine-threonine kinase that contains a Raf-like
Ras-binding domain (RBD encompassing amino acids
156 to 227), a protein kinase C-conserved region 1
domain (C1, amino acids 235 to 280) and a serine
threonine protein kinase catalytic domain (amino acids
456 to 712) [9]. BRAF is involved in the mitogen-acti-
vated protein kinase (MAPK) signalling pathway, which
regulates cell growth [10]. This pathway is also impli-
cated in the production of proinflammatory cytokines
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any medium, provided the original work is properly cited.leading to joint inflammation and destruction [11]. Acti-
vation of BRAF leads to activation of MEK1 and/or
MEK2. These kinases are the major substrates of BRAF
in mammalian cells [12].
We have observed that sera from RA patients recog-
nize the BRAF’s catalytic domain which encompasses
amino acids 416 to 766. To identify peptide targets of
anti-BRAF autoantibodies, we used 40 overlapping 20
mers encompassing the entire catalytic domain of BRAF
to analyze RA sera. We found that one BRAF peptide,
P25 (656 to 675), is specifically recognized by autoanti-
bodies from RA patients. Of interest, anti-P25 autoanti-
bodies are detected in 21% of anti-CCP negative RA
patients.
To test whether autoantibodies to BRAF influence
BRAF kinase activity, we developed a phosphorylation
assay with BRAF, its substrate MEK1 and purified anti-
BRAF autoantibodies from RA patients. We found that
anti-BRAF autoantibodies activate the in vitro phosphor-
ylation of MEK1 mediated by BRAF.
Materials and methods
RA patients
A total of 180 RA patients were chosen from the Rheu-
matology Ward at Hospital La Conception, Marseille,
France. These patients fulfilled the 1987 American Col-
lege of Rheumatology criteria for RA [13]. In every
patient, HLA-DR genotyping and anti-CCP titration was
obtained. One hundred, five RA patients were anti-CCP
positive and 75 RA patients were anti-CCP negative.
Ethical approval was obtained for this study; all partici-
pants gave their informed consent.
Controls
Sixty-five patients with ankylosing spondylitis (AS) and
27 patients with psoriasis arthritis (PsA) from the Rheu-
matology Ward at Hospital La Conception, Marseille, 60
volunteers from the staffs of INSERM UMR 639 and the
Marseille Blood Transfusion Center were tested. Ethical
approval was obtained for this study; all participants
gave their informed consent.
Synthetic peptides
Forty 20-mer peptides, overlapping by 10 aminoacids
and encompassing residues 416 to 766 of BRAF (locus
NP_004324.1) were synthesized using the solid phase
system and purified (Neosystem, Strasbourg, France).
This segment from BRAF is polymorphic at position
599 where the usual valine residue can be replaced by a
glutamate residue, a polymorphism associated with
increased kinase activity and observed in human cancers
[14,15].
Peptides P18 and P19 contain position 598 threonine
and a position 601 serine residues which are the targets
of phosphorylation during BRAF activation. Therefore,
we synthesized both their native and phosphorylated
forms, that is, P18 and its phosphorylated variants P35
(phosphorylated threonine 598), P36 (phosphorylated
serine 601), P37 (both phosphorylated threonine 598
and serine 601), P19 and its phosphorylated variants
P38 (phosphorylated threonine 598), P39 (phosphory-
lated serine 601) and P40 (both phosphorylated threo-
nine 598 and serine 601). Phosphorylated residues are
indicated in red in Figure 1.
Detection of autoantibodies by ELISA
Plates were coated overnight with 10 μg peptide per well
diluted in phosphate buffer saline (PBS), pH7.4. Plates
were blocked with PBS containing 5% milk. Sera diluted
to 1:100 in PBS were incubated for two hours on plates.
After washing with 0.1% Tween 20, peroxydase conju-
gated anti-human IgG (Sigma Aldrich, ST Quentin Fal-
lavier, France) was added. Optical density was read at
405 nm. Background OD was obtained by adding each
serum to a well without protein. A positive serum was
defined by an OD value more than twice background
OD [7,8,16].
Purification of autoantibodies to BRAF
Cyanogen bromide activated Sepharose 4B (Sigma
Aldrich) was washed with 1 mM HCl and incubated
with BRAF catalytic domain (amino acid 416-766,
NP_004324, Invitrogen, Cergy Pontoise, France) in 0.1
M NaHCO3 and 0.5 M NaCl pH8 buffer overnight at 4°
C. Free Sepharose groups were then blocked with 0.2 M
Glycin pH8 for two hours at room temperature. Col-
umns were washed at 4°C with the following buffers: 0.1
M NaHCO3, 0.5 M NaCl (pH8), then 0.5 M
CH3COONa (pH4) buffer and finally with phosphate
buffer pH7.
We selected 20 sera from RA patients, already known
to contain autoantibodies to BRAF. Sera were incubated
with 1 μg BRAF catalytic domain immobilized on
sepharose. After washing, autoantibodies to BRAF were
eluted in PBS pH2, neutralized in 1 M Tris and
quantified.
BRAF kinase assay
BRAF dependent phosphotransferase activity was mea-
sured in a kinase reaction using inactive recombinant
MEK1 as a BRAF substrate (BRAF kinase assay Kit, che-
miluminescence detection, Millipore Upstate Temecula,
CA, USA). Briefly, MEK1 was incubated for 30 minutes
at 30°C with 0.1 μg BRAF in working buffer in presence
of 0.1 μg purified autoantibodies to BRAF.
For each patient, we included one positive phosphory-
lation control (incubation of inactive MEK1 with BRAF
in working buffer) and one negative control (incubation
Charpin et al. Arthritis Research & Therapy 2010, 12:R194
http://arthritis-research.com/content/12/5/R194
Page 2 of 7of inactive MEK1 with BRAF in working buffer in pre-
sence of 0.1 μg control antibody C1). Control antibody
C1 is an anti-human PAD4 autoantibody purified from
RA patients’ sera by the same technique as anti-BRAF.
Proteins were then separated on 8% SDS page and
transferred onto PVDF membranes. Membranes were
blocked, incubated with anti-phospho MEK1 antibody
and revealed by chemiluminescence. Membranes were
scanned with a Gene Flash (Syngene Europe, Cam-
bridge, United Kingdom). Data were acquired with Gene
Tools software (Syngene Europe, Cambridge, United
Kingdom). Activation or inhibition of phosphorylation
was evaluated by measuring the ratio test OD/positive
control OD. A ratio of > 1 indicated activation while a
ratio of < 1 indicated inhibition. Three kinase assays
were performed separately for each patient and control.
Statistical analysis
P-values were calculated using the Chi square Test. P <
0.01 was considered significant.
Results
Autoantibodies to BRAF recognize four linear epitopes on
BRAF
To identify B cell epitopes on BRAF, we synthesized 40
overlapping 20 mer peptides encompassing the entire
catalytic domain of BRAF. We screened these 40 pep-
tides with the sera of 20 RA patients known to contain
autoantibodies to BRAF. Among the 40 peptides, 14
were recognized by at least one of the tested sera. Four
peptides, P10, P16, P25 and P33 were preferentially
recognized by the sera of RA patients. Indeed, 17 sera
recognized P10, 8 recognized P16, 15 recognized P25,
and 6 recognized P33 (Figure 1).
Peptide P25 on BRAF is specifically recognized by RA
patients
To confirm these reactivities, we tested, using ELISA,
the sera of 180 RA patients, 65 AS patients, 27 PsA
patients and 60 healthy individuals on P10, P16, P25
and P33.
BRAF Peptides 
1 2 3 4 5 6 7 8 9 1 01 11 21 31 41 51 61 71 81 92 0
1/ LQKSPGPQRERKSSSSSEDR
RA patients
2/ RKSSSSSEDRNRMKTLGRRD
3/ NRMKTLGRRDSSDDWEIPDG
4/ SSDDWEIPDGQITVGQRIGS
5/ QITVGQRIGSGSFGTVYKGK
6/ GSFGTVYKGKWHGDVAVKML
7/ WHGDVAVKMLNVTAPTPQQL
8/ NVTAPTPQQLQAFKNEVGVL
9/ QAFKNEVGVLRKTRHVNILL
10/ RKTRHVNILLFMGYSTKPQL
11/ FMGYSTKPQLAIVTQWCEGS
12/ AIVTQWCEGSSLYHHLHIIE
13/ SLYHHLHIIETKFEMIKLID
14/ TKFEMIKLIDIARQTAQGMD
15/ IARQTAQGMDYLHAKSIIHR
16/ YLHAKSIIHRDLKSNNIFLH
17/ DLKSNNIFLHEDLTVKIGDF
18/ EDLTVKIGDFGLATEKSRWS
19/ GLATEKSRWSGSHQFEQLSG
20/ GSHQFEQLSGSILWMAPEVI
21/ SILWMAPEVIRMQDKNPYSF
22/ RMQDKNPYSFQSDVYAFGIV
23/ QSDVYAFGIVLYELMTGQLP
24/ LYELMTGQLPYSNINNRDQI
25/ YSNINNRDQIIFMVGRGYLS
26/ IFMVGRGYLSPDLSKVRSNC
27/ PDLSKVRSNCPKAMKRLMAE
28/ PKAMKRLMAECLKKKRDERP
29/ CLKKKRDERPLFPQILASIE
30/ LFPQILASIELLARSLPKIH
31/ LLARSLPKIHRSASEPSLNR
32/ RSASEPSLNRAGFQTEDFSL
33/ AGFQTEDFSLYACASPKTPI
34/ ACASPKTPIQAGGYGAFPVH 34/ ACASPKTPIQAGGYGAFPVH
35/ EDLTVKIGDFGLATEKSRWS
36/ EDLTVKIGDFGLATEKSRWS
37/ EDLTVKIGDFGLATEKSRWS
38/ GLATEKSRWSGSHQFEQLSG
39/ GLATEKSRWSGSHQFEQLSG
40/ GLATEKSRWSGSHQFEQLSG
Figure 1 Autoantibodies to BRAF recognize four linear peptides P10, P16, P25, P33.A n t i - B R A Fa u t o a n t i b o d i e sf r o mt h es e r ao f2 0R A
patients were tested for binding to BRAF peptides by ELISA. After washing, peroxydase conjugated anti-human IgG was added. Optical density
was read at 405 nm. Background OD was obtained by adding each serum to a well without peptide. Positive sera were defined by OD value
higher than twice background OD (in blue).
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patients more often than in controls (Figure 2). Autoanti-
bodies to P10 were more sensitive but less specific for RA
than P25. Indeed, 35% of RA patients’ sera recognized P10
versus 18% of AS patients (P = 0.01), 4% of PsA patients
(P = 0.001) and 7% of healthy individuals (P = 0.00002).
Autoantibodies to P25 were very specific for RA.
Indeed, 19% of RA patients’ sera recognized P25 versus
1.5% of AS patients (P = 0.0006), 0% of PsA patients
(P = 0.01) and 0% of healthy individuals (P = 0.0003).
Autoantibodies to P16 were not commonly detected in
RA. Indeed, only 4% of RA patients’ sera recognized P16
versus 0% of AS patients, 0% of PsA patients and 0% of
healthy individuals (P = 0.008 180 RA patients versus
152 controls). Finally, autoantibodies to P33 were less
specific for RA. Indeed, 17% of RA patients, but also
14% of AS patients, 11% of PsA patients and 22% of
healthy individuals recognized P33 (P = 0.85, 180 RA
patients versus 152 controls).
Peptide P25 on BRAF identifies RA in 21% of anti-CCP
negative RA patients
Autoantibodies to P25 were analyzed by ELISA in 105 anti-
CCP positive and 75 anti-CCP negative patients. Among
anti-CCP positive patients, 17% recognized P25. Among
anti-CCP negative patients, 21% recognized P25 (Figure 2).
Autoantibodies to BRAF activate the phosphorylation of
MEK1 by BRAF
To test whether autoantibodies directed to BRAF inter-
fere with its enzymatic activity, we analyzed the
phosphorylation of MEK1 in presence of BRAF and
autoantibodies to BRAF purified from 20 RA patients.
Autoantibodies to BRAF were purified from RA
patient’s sera and their presence was confirmed by dot
blot (data not shown). After quantification of purified
autoantibodies to BRAF, we tested the phosphorylation
of MEK1 in presence of BRAF and autoantibodies to
BRAF purified from 20 RA patients. Phosphorylation of
MEK1 by BRAF was detected by Western blotting and
quantified. A mean ratio was obtained from three sepa-
rate assays. A ratio of > 1 indicated activation, a ratio of
< 1 indicated inhibition.
Among 20 purified autoantibodies to BRAF, 1 inhib-
ited and 13 activated MEK1 phosphorylation (Figure 3).
We can’t conclude for six autoantibodies to BRAF (RA4,
RA2, RA17, RA13, RA15, and RA16). Indeed, a ratio of
≥1 was obtained but with a strong variability.
Among autoantibodies to BRAF that activated MEK1
phosphorylation, 10/13 were weak activators (1 < ratio <
1.5) and 3/13 were strong activators (ratio > 1.5).
No difference was observed in the recognition of
BRAF peptides between autoantibodies to BRAF that
inhibited or activated MEK1 phosphorylation (data not
shown).
Discussion
RA is an autoantibody mediated disease. The sera of
patients with RA contain a family of highly disease-spe-
cific autoantibodies termed ACPA which recognize
citrulline-centered peptidic epitopes on many proteins,
like filaggrin, vimentin, and fibrin. Citrullyls are arginyl
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Figure 2 Recognition of BRAF peptides in RA patients and controls. Anti-BRAF autoantibodies from the sera of RA, AS, PsA patients and
healthy controls were tested for binding to BRAF peptides by ELISA. After washing, peroxydase conjugated anti-human IgG was added. Optical
density was read at 405 nm. Background OD was obtained by adding each serum to a well without peptide. Positive sera were defined by OD
value higher than twice background OD.
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basic form into a neutral variant by a posttranslational
modification called deimination, mediated by peptidylar-
g i n i n ed e i m i n a s e s .A C P A sc a nb ed e t e c t e db yac o m -
mercial ELISA assay containing a synthetic cyclic
citrullinated peptide and identify 60% of RA patients.
However, non-citrullinated proteins can also be the tar-
get of autoantibodies in RA. For instance RA-associated
HLA-DR alleles are associated with presence of autoan-
tibodies to synovial calpastatin in RA patients’ sera [7].
We also identified peptidyl arginine deiminase 4 (PAD4)
as an RA specific autoantigen [8,16].
By using protein arrays, we recently found that BRAF is
a major non-citrullinated autoantigen in RA. Indeed, 35%
of RA patients’ sera contain autoantibodies to BRAF’s
catalytic domain versus 4% of ankylosing spondylitis
patients’ and 6% of healthy individuals’.I nt h i ss t u d y ,w e
mapped epitopes in the BRAF’s catalytic domain and
analysed the function of anti-BRAF autoantibodies.
To identify peptides targets of anti-BRAF autoantibo-
dies, we used a direct ELISA using a set of synthetic
peptides and the sera of RA patients. We identified two
linear peptides on BRAF, P10 and P25, recognized pre-
ferentially by RA patients. Peptides P10 (506 to 525)
and P25 (656 to 675) are located in the catalytic domain
of BRAF.
P10 is more sensitive but less specific than P25. P10 is
recognized by 35% of RA patients versus 11% of con-
trols (P <1 0
-7, 180 RA patients versus 152 controls).
P25 might have diagnostic interest. Indeed, P25 is
recognized by 19% of RA patients versus 0.7% of con-
trols (P <1 0
-7, 180 RA patients versus 152 controls). Of
higher interest, P25 is recognized by 21% of anti-CCP
negative patients. Therefore, P25 could be used to diag-
nose RA in anti-CCP negative patients.
We then analysed the effects of anti-BRAF autoantibo-
dies isolated from RA patients on the kinase activity of
BRAF. Indeed, autoantibodies directed to an enzyme
may interfere with its function. For example, we have
recently shown that RA specific autoantibodies to PAD4
inhibit PAD4 mediated citrullination in vitro [16]. BRAF
is also an interesting target for autoantibodies. Indeed,
BRAF is a serine-threonine kinase involved in the trans-
duction of mitogenic signals from the cell membrane to
the nucleus. BRAF regulates the mitogen-activated pro-
tein kinase (MAPK) signalling cascade. A simplified and
linear representation of this cascade comprises RAS,
BRAF, MEK and ERK [17]. RAS activation is the first
step in the activation of the MAPK cascade. Following
RAS activation, BRAF is recruited to the cell membrane
and then phosphorylates MEK in the cytoplasm. Acti-
vated MEK subsequently phosphorylates ERK, which
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Figure 3 Autoantibodies to BRAF activate the phosphorylation of MEK1. Purified anti-BRAF autoantibodies from patients were incubated
with BRAF and MEK1. For each patient, we included one positive control (BRAF and MEK1) and one negative control (BRAF and MEK1 and C1
control antibody). Activation or inhibition of MEK1 phosphorylation was detected by measuring the ratio test OD/positive control OD. Ratio > 1
indicated activation, ratio < 1 indicated inhibition. Bars showed the mean ratio ± SD.
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Page 5 of 7translocates to the nucleus where it activates multiple
transcription factors.
MAPKs are involved in signalling via the B cell anti-
gen receptor, T cell receptor, Toll-like receptor and
IL-1, IL-17 and TNFa receptors. MAPKs also play key
roles in the production of pro-inflammatory cytokines
(TNFa, IL-1, IL-6). In particular, p38 MAPK is
expressed in the RA synovium and regulates the produc-
tion of pro-inflammatory cytokines [18,19]. Inhibitors of
p38 MAPK reduce osteoclast activation and prevent the
development of collagen-induced arthritis in the mouse
[20,21]. However, so far, p38 MAPK inhibition showed
modest clinical efficacy in patients with RA [22].
To test whether autoantibodies to BRAF may influ-
ence BRAF activity as a kinase, we developed a phos-
phorylation assay using BRAF, MEK1 (its major
substrate) and autoantibodies to BRAF purified from RA
patients’ sera. We observed that 65% of anti-BRAF auto-
antibodies activate phosphorylation of MEK1 by BRAF
in vitro. Thus, we suggest that anti-BRAF autoantibodies
could activate the MAP kinase pathway through BRAF,
leading to pro-inflammatory cytokine production and
joint inflammation.
We propose a model to explain how autoantibodies to
BRAF may activate BRAF (Figure 4). Although BRAF is
an intracellular protein, it could be recognized by auto-
antibodies outside the cell, because in RA, cell death
may release BRAF from cells. Autoantibodies to BRAF
might enter the cell later as immune complexes. After
immune complexe dissociation, autoantibodies to BRAF
become accessible to intracellular BRAF. BRAF activa-
tion is regulated by both its N and C terminal domains.
The N terminal domain is responsible for the fixation of
BRAF to RAS. The C terminal domain contains the sub-
strate recognition sequence allowing MEK’s phosphory-
lation [23,24]. The binding of autoantibodies to BRAF’s
catalytic domain may result in a change in BRAF con-
formation and stabilise BRAF in an active conformation
allowing the kinase domain to contact its activators and
substrates. Testing this model in vivo will be our next
goal.
Conclusions
We have described a new family of autoantibodies asso-
ciated with RA. We have demonstrated here that these
autoantibodies activate BRAF, which is the first step in
MAP kinase activation. Fine epitope mapping on BRAF
enabled us to identify one peptide epitope, P25 which
may prove interesting in the diagnostic of RA, especially
in anti-CCP negative patients.
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Figure 4 A model to explain how autoantibodies to BRAF may activate BRAF. (A) In RA, cell death may release BRAF outside the cell and
BRAF could be recognized by autoantibodies. (B) Autoantibodies to BRAF might enter the cell as immune complexes. (C) Immune complexes
could be dissociated. Autoantibodies to BRAF might access to intracellular BRAF, stabilize BRAF in active conformation by binding its catalytic
domain and provoke MAP kinase activation.
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